*****
TODAY’S NEWS
Novartis gets niche transplant drug approved in US – Drug developer Novartis AG said Thursday it received Food and Drug Administration for the organ-rejection drug Zortress. The drug was first approved outside the U.S. six years ago as Certican and is available in more than 70 countries. It is used to prevent organ rejection in kidney transplant patients. The company reported $118 million in sales in 2009…more. Meanwhile, ex-Novartis executive moves on to head up Bayer HealthCare.
Merck growing its vaccines business with an acquisition.
Patient adherence: an immensely costly problem – Medical costs of patient non-adherence to therapy costs the US $106 billion each year, according to an Express Scripts study, and missed opportunities for use of cheaper meds and delivery systems costs another $57 billion…more
RECOMMENDED
eLearning Simulations – One of the best ways to learn, when things cannot be done live/on-site, is with well-crafted simulations. The Impactiviti Partner Network is your resource if you’re looking for great partners in technology and instructional design. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
The Intersection of Life, Business, and Social Media. According to me. In 2 graphics.
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Leave a Reply